Why is the Alcidion share price crashing 27% to a 52-week low?

This healthcare technology company is having a day to forget on Wednesday.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Alcidion Group Ltd (ASX: ALC) share price has returned from its trading halt and sunk deep into the red.

At the time of writing, the healthcare technology company's shares are down 27% to a 52-week low of 7.1 cents.

A woman holds her hands to the side of her face as she sits back in shock at something she is reading or seeing on her computer screen.

Image source: Getty Images

What's going on with the Alcidion share price today?

There have been a couple of catalysts for the weakness in the Alcidion share price on Wednesday.

The first has been the company undertaking a capital raising. According to the release, Alcidion has received firm commitments to raise $5 million through an institutional placement. These funds are being raised at 7.5 cents per new share, which is a 23% discount to its last close price.

In addition, Alcidion is aiming to raise a further $1 million via a share purchase plan at the same price.

These funds are being raised to maintain a strong balance sheet so it can execute on its market opportunities and drive ongoing revenue growth.

What else?

The company's quarterly update doesn't appear to have gone down too well with investors and could also be weighing on the Alcidion share price today.

Alcidion reported new total contract value of $2.5 million for the quarter, which is up 39% on the prior corresponding period. This means that total contracted revenue was $35.3 million at the end of the quarter, which is up 12% on the prior corresponding period.

And while management has maintained its expectation to be EBITDA and operating cashflow positive in FY 2024, its first quarter performance is certainly not supportive of this.

Alcidion revealed quarterly cash receipts of $6.4 million and negative operating cash flow of $8 million. A big portion of this outflow relates to staff costs, which came in at a lofty $8.5 million.

This reduced its cash balance from $14.6 million at the end of June to just $6.5 million. Though, this excludes the money raised from its capital raising.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Alcidion Group. The Motley Fool Australia has recommended Alcidion Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Up 1,173% in a year, what do 4DMedical shares have over other healthcare stocks?

Expert explains why 4DMedical is somewhat sheltered from today's sector headwinds.

Read more »

A couple sits on the bed in their hotel room wearing white robes, both have seen the bad news on their phones.
Earnings Results

What's going on with ResMed shares today?

The sleep disorder treatment company has released its third-quarter update this morning.

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Healthcare Shares

Resmed reports double-digit revenue and profit increases in Q3 FY26

Resmed posted double-digit revenue and profit growth in Q3 FY26, with management confident about continued momentum.

Read more »

a woman puts her fingers in her ears with a pained expression on her face with her eyes closed as though trying to block hearing bad news or an unpleasant loud noise.
Healthcare Shares

Cochlear shares crashed in April, but is a comeback looming?

This ASX 200 healthcare stock is caught between short-term pain and long-term potential.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder, as if giving comfort.
Healthcare Shares

What's making healthcare the worst sector on the ASX 200, down 39% in a year?

An expert outlines the key headwinds weighing on the industry and share prices today.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

Good news, falling shares: What's dragging this ASX stock lower?

In biotech, strong updates don't always push the share price higher.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Healthcare Shares

Guess which ASX All Ords healthcare share is rocketing 18% in Thursday's sinking market

Investors are piling into the ASX healthcare share on Thursday. But why?

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Healthcare Shares

Mesoblast shares: Cash burn falls and Ryoncil® sales climb

Mesoblast reports higher Ryoncil® sales, improved cash management, and research milestones for the March 2026 quarter.

Read more »